The decision, in one paragraph
Both paths require the same regulatory floor: a Brazilian entity with an active AFE, a licensed Technical Responsible (RT), and full ANVISA notification or registration for the product itself. Neither path is a shortcut around ANVISA. The real trade-off is speed, control, and capital: direct import gets your exact existing product to market faster but with less local flexibility; local contract manufacturing takes longer to set up but scales more efficiently once running, and often costs less per unit at volume.
Not sure which path fits your brand?
The right answer depends on your volume, timeline, and how much formula flexibility you need for the Brazilian market. Book a paid consulting session for a direct comparison specific to your product.
→ Book a Paid Consulting Session (WhatsApp)What’s identical either way
An AFE (Autorização de Funcionamento de Empresa) is valid for 2 years and must be renewed to maintain legal operating status, regardless of which path you choose.
| Requirement | Direct Import | Local Manufacturing |
|---|---|---|
| Brazilian legal entity required | Yes | Yes |
| AFE (company operating authorization) | Required, 2-year validity | Required, 2-year validity |
| Licensed Technical Responsible (RT) | Required | Required |
| ANVISA product notification/registration | Required, per product | Required, per product |
| Stability and dosage documentation | Required | Required |
Where the two paths actually diverge
Direct Import
- Your existing formula ships as-is, no reformulation for local ingredients
- Faster to market if your product already clears ANVISA’s approved ingredient list
- Subject to import logistics, customs clearance timing, and currency exposure on every shipment
- Less flexibility to adapt quickly to local consumer preferences or pricing pressure
Local Contract Manufacturing
- White label (use an existing validated formula) or custom formula development from scratch
- Full-service manufacturers handle formulation, encapsulation, labeling, and ANVISA notification together
- Minimum order quantities commonly start around 300 units per formula
- No import logistics or currency risk per shipment once production is local
The RT cost detail most brands don’t budget for
Both paths require a licensed Technical Responsible, a pharmacist or qualified professional who signs for the product’s compliance. An outsourced RT, serving multiple client companies simultaneously, typically runs R$800 to R$2,500 per month depending on volume and complexity (source). This is an ongoing operating cost, not a one-time fee, and it applies whether you import or manufacture locally.
Brazil is the third-fastest-growing major market for this category
According to Future Market Insights data, Brazil ranks third globally in projected supplement demand growth, at an average annual rate of 9.5% between 2026 and 2036, trailing only India and China. Getting the import-vs-manufacture decision right early matters more in a market moving this fast, a slow start compounds against a rapidly shifting competitive landscape.
Vetting a local manufacturer, if you choose that path
Before signing with any Brazilian contract manufacturer, verify Boas Práticas de Fabricação (BPF) certification, Brazil’s baseline Good Manufacturing Practices standard (source). ISO 9001 quality management certification is a further positive signal. Check the manufacturer’s compliance history directly on ANVISA’s public portal, not just their own marketing claims, an active facility with a clean regulatory record is not the same as one simply claiming compliance.
Weighing import against local manufacturing?
Book a paid consulting session for a straight comparison of both paths for your specific product and volume, before you commit capital to either one.
→ Book a Paid Consulting Session (WhatsApp) → Email: wagner@farmacerto.comRelated Reading
Why 65% of New Supplements Get Rejected by ANVISA Brazil’s Supplement Notification Deadline: What Happened The Labeling Mistake That Delays Every Brazil LaunchFrequently Asked Questions
References: ANVISA, AFE (Autorização de Funcionamento de Empresa) regulatory framework, RDC 16/2014. ANVISA, RDC 843/2024, supplement notification and adequacy requirements. Future Market Insights, Brazil dietary supplement market growth projections, 2026-2036. Pronutrition, “Terceirização de Suplementos: O que analisar antes de contratar,” industry analysis, 2026. Veridi Nutrition, full-service contract manufacturing model documentation. Sanrisil, RDC 843/2024 compliance guidance for contract manufacturing.
Descubra mais sobre FarmaCerto
Assine para receber nossas notícias mais recentes por e-mail.